1. A 52‐week update of a multicentre real‐life experience on effectiveness and safety of risankizumab in psoriasis. (19th September 2021) Authors: Hansel, K.; Zangrilli, A.; Bianchi, L.; Peris, K.; Chiricozzi, A.; Offidani, A.; Diotallevi, F.; Fargnoli, M.C.; Esposito, M.; Amerio, P.; Gualdi, G.; Bianchi, L.; Stingeni, L. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 36:Number 2(2022) Page Start: e111 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16‐week real‐life experience during the COVID‐19 pandemic. (8th November 2020) Authors: Hansel, K.; Zangrilli, A.; Bianchi, L.; Peris, K.; Chiricozzi, A.; Offidani, A.; Diotallevi, F.; Fargnoli, M.C.; Esposito, M.; Amerio, P.; Gualdi, G.; Bianchi, L.; Stingeni, L. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 35:Number 3(2021) Page Start: e169 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A revolutionary therapeutic approach for psoriasis: bispecific biological agents. (2nd July 2016) Authors: Torres, T.; Romanelli, M.; Chiricozzi, A. Journal: Expert opinion on investigational drugs Issue: Volume 25:Number 7(2016:Jul.) Page Start: 751 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Certolizumab for the treatment of psoriasis and psoriatic arthritis: a real‐world multicentre Italian study. (26th June 2020) Authors: Dattola, A.; Balato, A.; Megna, M.; Gisondi, P.; Girolomoni, G.; De Simone, C.; Caldarola, G.; Cama, E.; Piaserico, S.; Fargnoli, M.C.; Fidanza, R.; Parodi, A.; Burlando, M.; Offidani, A.; Diotallevi, F.; Potenza, C.; Conti, A.; Chiricozzi, A.; Campione, E.; Bianchi, L. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 34:Number 12(2020) Page Start: 2839 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Consensus on the place in therapy of TNF‐α inhibitors in the treatment of patients with chronic plaque psoriasis. (20th May 2020) Authors: Gisondi, P.; Bellinato, F.; Conti, A.; Dapavo, P.; Piaserico, S.; De Simone, C.; Chiricozzi, A.; Dattola, A.; Malagoli, P.; Malara, G.; Campanati, A.; Burlando, M.; Esposito, M.; Gallo, L.; Girolomoni, G. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 34:Number 9(2020) Page Start: e470 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Creation of a severity index for hidradenitis suppurativa that includes a validated quality‐of‐life measure: the HIDRAscore. (12th May 2020) Authors: Marzano, A.V.; Chiricozzi, A.; Giovanardi, G.; Argenziano, G.; Bettoli, V.; Bianchi, L.; Dapavo, P.; Dini, V.; Fabbrocini, G.; Micali, G.; Offidani, A.M.; Potenza, C.; Prignano, F.; Gualberti, G.; Saragaglia, V.; Rongioletti, F. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 34:Number 8(2020) Page Start: 1815 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Effectiveness of Secukinumab in the treatment of moderate–severe hidradenitis suppurativa: results from an Italian multicentric retrospective study in a real‐life setting. (9th March 2021) Authors: Ribero, S.; Ramondetta, A.; Fabbrocini, G.; Bettoli, V.; Potenza, C.; Chiricozzi, A.; Licciardello, M.; Marzano, A.V.; Bianchi, L.; Rozzo, G.; Fania, L.; Marasca, C.; Odorici, G.; Mambrin, A.; Moltrasio, C.; Caposiena Caro, R.D.; Skroza, N.; Quaglino, P.; Siliquini, N.; Dapavo, P. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 35:Number 7(2021) Page Start: e441 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience. (1st June 2019) Authors: Conti, A.; Peccerillo, F.; Amerio, P.; Balato, A.; Bardazzi, F.; Bianchi, L.; Burlando, M.; Cannavò, S.P.; Chiricozzi, A.; Dapavo, P.; De Simone, C.; Fargnoli, M.C.; Gambardella, A.; Gisondi, P.; Malagoli, P.; Malara, G.; Mugheddu, C.; Offidani, A.M.; Piaserico, S.; Prignano, F. Journal: British journal of dermatology Issue: Volume 180:Number 6(2019) Page Start: 1547 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience. (21st February 2019) Authors: Conti, A.; Peccerillo, F.; Amerio, P.; Balato, A.; Bardazzi, F.; Bianchi, L.; Burlando, M.; Cannavò, S.P.; Chiricozzi, A.; Dapavo, P.; De Simone, C.; Fargnoli, M.C.; Gambardella, A.; Gisondi, P.; Malagoli, P.; Malara, G.; Mugheddu, C.; Offidani, A.M.; Piaserico, S.; Prignano, F. Journal: British journal of dermatology Issue: Volume 180:Number 6(2019) Page Start: 1547 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Elderly psoriatic patients under biological therapies: an Italian experience. (6th July 2018) Authors: Ricceri, F.; Bardazzi, F.; Chiricozzi, A.; Dapavo, P.; Ferrara, F.; Mugheddu, C.; Romanelli, M.; Rongioletti, F.; Prignano, F. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 33:Number 1(2019) Page Start: 143 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗